227 related articles for article (PubMed ID: 30254491)
21. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
Gao Y; Shen J; Choy E; Mankin H; Hornicek F; Duan Z
Cell Oncol (Dordr); 2017 Jun; 40(3):209-218. PubMed ID: 28243976
[TBL] [Abstract][Full Text] [Related]
22. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
23. Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations.
Das A; Alshareef M; Martinez Santos JL; Porto GBF; McDonald DG; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Clin Transl Oncol; 2020 Nov; 22(11):2017-2025. PubMed ID: 32253706
[TBL] [Abstract][Full Text] [Related]
24. A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Bantie L; Tadesse S; Likisa J; Yu M; Noll B; Heinemann G; Lokman NA; Ricciardelli C; Oehler MK; Beck A; Pradhan R; Milne R; Albrecht H; Wang S
Gynecol Oncol; 2020 Dec; 159(3):827-838. PubMed ID: 32958271
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR.
Qin WJ; Su YG; Ding XL; Zhao R; Zhao ZJ; Wang YY
Am J Transl Res; 2022; 14(3):1616-1627. PubMed ID: 35422963
[TBL] [Abstract][Full Text] [Related]
27. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
[No Abstract] [Full Text] [Related]
28. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
[TBL] [Abstract][Full Text] [Related]
29. Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer.
Klein FG; Granier C; Zhao Y; Pan Q; Tong Z; Gschwend JE; Holm PS; Nawroth R
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33923231
[TBL] [Abstract][Full Text] [Related]
30. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
31. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.
Xue Z; Lui VWY; Li Y; Jia L; You C; Li X; Piao W; Yuan H; Khong PL; Lo KW; Cheung LWT; Lee VHF; Lee AWM; Tsao SW; Tsang CM
J Exp Clin Cancer Res; 2020 Nov; 39(1):262. PubMed ID: 33243298
[TBL] [Abstract][Full Text] [Related]
33. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in
Haines E; Chen T; Kommajosyula N; Chen Z; Herter-Sprie GS; Cornell L; Wong KK; Shapiro GI
Oncotarget; 2018 Aug; 9(60):31572-31589. PubMed ID: 30167080
[TBL] [Abstract][Full Text] [Related]
34. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
35. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Gul A; Leyland-Jones B; Dey N; De P
Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
[TBL] [Abstract][Full Text] [Related]
36. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
[TBL] [Abstract][Full Text] [Related]
37. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Bollard J; Miguela V; Ruiz de Galarreta M; Venkatesh A; Bian CB; Roberto MP; Tovar V; Sia D; Molina-Sánchez P; Nguyen CB; Nakagawa S; Llovet JM; Hoshida Y; Lujambio A
Gut; 2017 Jul; 66(7):1286-1296. PubMed ID: 27849562
[TBL] [Abstract][Full Text] [Related]
39. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
Digiacomo G; Fumarola C; La Monica S; Bonelli MA; Cretella D; Alfieri R; Cavazzoni A; Galetti M; Bertolini P; Missale G; Petronini PG
Front Oncol; 2020; 10():563249. PubMed ID: 33072590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
